Precision Medicine Perspectives

Recent Advances in the Treatment of Advanced/Metastatic NSCLC

November 14th 2022

Evolution of First-Line Immune Checkpoint Inhibition in Advanced or Metastatic Solid Tumors

November 8th 2022

This digital series explores the evolving first-line treatment landscape of advanced or metastatic solid tumors, including non-small cell lung cancer, with an emphasis on the use of immune checkpoint inhibitors alone or in combination with other treatment modalities.

NTRK Gene Fusions

August 15th 2022

Tumor-Infiltrating Lymphocytes in the Treatment of Solid Tumors

August 5th 2022

This digital series highlights the mechanistic rationale behind use of tumor-infiltrating lymphocytes in solid tumors, including NSCLC, and addresses the possible challenges and benefits of this treatment approach.

Exploring CAR T-Cell Therapy in Patients with Mantle Cell Lymphoma

August 2nd 2022

This series explores the development and clinical utility of CAR T-cell therapy in treating patients with mantle cell lymphoma.

Advances in the Treatment of NTRK Fusion-positive Cancers

December 23rd 2021

This series explores new developments in the molecular pathology and management of NTRK fusion-positive cancers.

Addressing Myelotoxicity as a Consequence of Treatment for Extensive-Stage Small Cell Lung Cancer

September 20th 2021

This digital series raises awareness regarding the challenges in treating extensive-stage small cell lung cancer through a review of the current treatment landscape, recently approved therapeutics, and emerging options for addressing the consequences of treatment.

New Precision Medicine Approaches in Advanced Prostate Cancer

August 30th 2021

This digital series raises awareness regarding the evolving spectrum of precision medicine in advanced prostate cancer through a review of the genomic testing and biomarker landscape as well as the rapidly developing treatment armamentarium, with an emphasis on the potential impact of these newer therapies.

BTK Inhibitors: In-Focus

April 27th 2021

This series highlights the evolving role of BTK inhibitors for the treatment of CLL.